• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

In this scientific statement from the American Heart Association, experts in the field of
cardiomyopathy (heart muscle disease) in children address 2 issues: the most current …

This guideline describes the approach and expertise needed for the genetic evaluation of
cardiomyopathy. First published in 2009 by the Heart Failure Society of America (HFSA), the …

Background: The clinical outcomes of noncompaction cardiomyopathy (NCCM) range from
asymptomatic to heart failure, arrhythmias, and sudden cardiac death. Genetics play an …

Background: Left ventricular noncompaction cardiomyopathy (LVNC) was discovered half a
century ago as a cardiomyopathy with excessive trabeculation and a thin ventricular wall. In …

Excessive trabeculation, often referred to as “noncompacted” myocardium, has been
described at all ages, from the fetus to the adult. Current evidence for myocardial …

Background The prognosis of left ventricular noncompaction (LVNC) remains elusive
despite its recognition as a clinical entity for> 30 years. We sought to identify clinical and …

Purpose To characterize the genetic architecture of left ventricular noncompaction (LVNC)
and investigate the extent to which it may represent a distinct pathology or a secondary …

Background A genetic cause can be identified in 30% of noncompaction cardiomyopathy
patients (NCCM) with clinical features ranging from asymptomatic cardiomyopathy to heart …

Background Left ventricular non-compaction has been increasingly diagnosed in recent
years. However, it is still debated whether non-compaction is a pathological condition or a …